Evidence on new anti-fibrotic medications included in international respiratory societies’ clinical IPF treatment guideline update
Lung Foundation Australia welcomes the updated guidelines on the treatment of idiopathic pulmonary fibrosis published by an international group of respiratory societies. These guidelines are important as they include the evidence on new anti-fibrotic medications and recent findings about other treatments. With the anticipated introduction of these anti-fibrotic medications in Australia it is important that local physicians are aware of these Guidelines.
The guidelines update evidence from 2011 and are published by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association in the American Journal of Respiratory and Critical Care Medicine, led by its Chair Prof. Ganesh Raghu.
The guideline recommendations when applied in practice must be evaluated individually, considering all the factors, including the desirable and undesirable consequences of treatment, treatment costs, the implications of treatment on health equity, and the feasibility of treatment.
An executive summary and the full guidelines are available on the American Thoracic Society website click here.
Clinical trials for IPF medications in Australia
Apart from creating a unique research platform, the Australian IPF Registry also aims to improve recruitment to clinical trials for new potential medications. Tabled are the clinical trials in IPF that are currently being or have recently been undertaken in Australia.
|Study||Therapeutic agent||Company||Trial Phase||Progress|
|ASCEND||Pirfenidone||InterMune||Phase III||Recruitment complete.|
|BIBF 1120||Nintedanib||Boehringer Ingelheim||Phase III||Recruitment complete.|
|NCT01629667||Tralokinumab||MedImmune||Phase II||Ongoing recruitment|
|NCT01769196||Simtuzumab||Gilead||Phase II||Ongoing recruitment|
|Lebrikizumab||Roche||Phase II||Ongoing recruitment*|
|RISE-IIP||Riociguat||Bayer||Phase II||Ongoing recruitment*|
|BMS-986020||Bristol-Myers Squibb||Phase II||Ongoing recruitment|
* Clinical trials that now include anti-fibrotics in the placebo arm
Table 1. Clinical trials for potential IPF medications in Australia
For further information on these trials, please contact the Interstitial Lung Disease clinical trial centre/s in your State.
Australian IPF Registry research to be presented at ERS 2015
The Australian IPF Registry research into the quality of life of patients with Idiopathic Pulmonary Fibrosis (IPF) has been selected for oral presentation at the European Respiratory Society International Congress in Amsterdam this year.
Quality of life of patients with Idiopathic Pulmonary Fibrosis (IPF) – What can the Australian IPF Registry tell us?, will be presented at the “IPF clinical” session on Wednesday 30 September from 10:45 to 12:45 in “Room Forum”.
A/Professor Tamera Corte will also be presenting registry research during the Satellite Symposium, on Monday 28 September 2015 at 17.15-19.15, Idiopathic pulmonary fibrosis – where real world meets science. Organised by Boehringer Ingelheim International GmbH.